Literature DB >> 9462474

The level of cerebrospinal fluid tau correlates with neurofibrillary tangles in Alzheimer's disease.

T Tapiola1, M Overmyer, M Lehtovirta, S Helisalmi, J Ramberg, I Alafuzoff, P Riekkinen, H Soininen.   

Abstract

We measured tau concentrations in cerebrospinal fluid (CSF) samples taken during the lifetime of 43 patients with Alzheimer's disease (AD) and correlated these values with neurofibrillary tangle (NFT) scores as well as glial fibrillary acidic protein (GFAP) expression as a marker of astrocytosis in the brain post-mortem. The CSF tau values showed a positive correlation with neocortical NFT scores (r = 0.44, p < 0.005), while GFAP immmunoreactivity did not correlate with CSF tau. This study reveals a high variation in CSF tau values in patients with neuropathologically confirmed AD (range 194-1539 pg/ml) and indicates that high CSF tau values in the late phase of Alzheimer's disease predict severe neurodegeneration as evidenced by increased NFT scores.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9462474     DOI: 10.1097/00001756-199712220-00022

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  35 in total

1.  The impact of cerebrospinal fluid biomarkers on the diagnosis of Alzheimer's disease.

Authors:  Sebastiaan Engelborghs; Nathalie Le Bastard
Journal:  Mol Diagn Ther       Date:  2012-06-01       Impact factor: 4.074

2.  Tau in cerebrospinal fluid: a sensitive sandwich enzyme-linked immunosorbent assay using tyramide signal amplification.

Authors:  Hidenaga Yamamori; Sabiha Khatoon; Inge Grundke-Iqbal; Kaj Blennow; Michael Ewers; Harald Hampel; Khalid Iqbal
Journal:  Neurosci Lett       Date:  2007-03-14       Impact factor: 3.046

3.  Decreased cerebrospinal fluid Abeta(42) correlates with brain atrophy in cognitively normal elderly.

Authors:  Anne M Fagan; Denise Head; Aarti R Shah; Daniel Marcus; Mark Mintun; John C Morris; David M Holtzman
Journal:  Ann Neurol       Date:  2009-02       Impact factor: 10.422

4.  Problems associated with biological markers of Alzheimer's disease.

Authors:  H J Frey; K M Mattila; M A Korolainen; T Pirttilä
Journal:  Neurochem Res       Date:  2005-12       Impact factor: 3.996

5.  MRI and CSF biomarkers in normal, MCI, and AD subjects: predicting future clinical change.

Authors:  P Vemuri; H J Wiste; S D Weigand; L M Shaw; J Q Trojanowski; M W Weiner; D S Knopman; R C Petersen; C R Jack
Journal:  Neurology       Date:  2009-07-28       Impact factor: 9.910

6.  Body mass index is associated with biological CSF markers of core brain pathology of Alzheimer's disease.

Authors:  Michael Ewers; Susanne Schmitz; Oskar Hansson; Cathal Walsh; Annette Fitzpatrick; David Bennett; Lennart Minthon; John Q Trojanowski; Leslie M Shaw; Yetunde O Faluyi; Bruno Vellas; Bruno Dubois; Kaj Blennow; Katharina Buerger; Stefan J Teipel; Michael Weiner; Harald Hampel
Journal:  Neurobiol Aging       Date:  2011-06-17       Impact factor: 4.673

7.  Evidence for ordering of Alzheimer disease biomarkers.

Authors:  Clifford R Jack; Prashanthi Vemuri; Heather J Wiste; Stephen D Weigand; Paul S Aisen; John Q Trojanowski; Leslie M Shaw; Matthew A Bernstein; Ronald C Petersen; Michael W Weiner; David S Knopman
Journal:  Arch Neurol       Date:  2011-08-08

8.  The relationship between CSF biomarkers and cerebral metabolism in early-onset Alzheimer's disease.

Authors:  Alice Jaillard; Matthieu Vanhoutte; Aurélien Maureille; Susanna Schraen; Emilie Skrobala; Xavier Delbeuck; Adeline Rollin-Sillaire; Florence Pasquier; Stéphanie Bombois; Franck Semah
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-08-28       Impact factor: 9.236

Review 9.  Emerging biomarkers in cognition.

Authors:  Meredith Wicklund; Ronald C Petersen
Journal:  Clin Geriatr Med       Date:  2013-11       Impact factor: 3.076

10.  Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade.

Authors:  Clifford R Jack; David S Knopman; William J Jagust; Leslie M Shaw; Paul S Aisen; Michael W Weiner; Ronald C Petersen; John Q Trojanowski
Journal:  Lancet Neurol       Date:  2010-01       Impact factor: 44.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.